Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study

Trial Profile

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Embolism; Stroke; Thromboembolism
  • Focus Adverse reactions
  • Acronyms XANAP
  • Sponsors Bayer
  • Most Recent Events

    • 20 May 2016 Status changed from recruiting to completed.
    • 18 Jul 2014 Planned primary completion date changed from 1 Jul 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 28 Jan 2014 Planned number of patients changed from 7000 to 2300 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top